Drug Profile


Alternative Names: N 91115

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator N30 Pharma
  • Developer Nivalis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 18 Apr 2017 Discontinued - Phase-II for Cystic fibrosis (Adjunctive treatment) in USA (PO)
  • 13 Feb 2017 Nivalis Therapeutics has patent pending for cavosonstat in USA and other countries (Nivalis Therapeutics Form 10-K, February 2017)
  • 13 Feb 2017 Nivalis Therapeutics has patent protection for cavosonstat in USA (Nivalis Therapeutics Form 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top